Aleksandra Šliachtenko

Aleksandra Šliachtenko

Auto-generated profile, based on publicly available information

Aleksandra Šliachtenko

Center of Neurology, Vilnius University, Vilnius, Lithuania

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2024 in Expert Opinion on Drug Discovery
Verified
Journal Article
Closed access
JVJulija Valančienė
Julija Valančienė
Kazimieras MelaikaKazimieras Melaika
Kazimieras Melaika
AŠAleksandra Šliachtenko
Aleksandra Šliachtenko
KŠKamilė Šiaurytė-Jurgelėnė
Kamilė Šiaurytė-Jurgelėnė
AEAleksandra Ekkert
Aleksandra Ekkert
Dalius JatuzisDalius Jatuzis
Dalius Jatuzis
Stroke is one of the main causes of death and disability worldwide. Nevertheless, despite the global burden of this disease, our understanding is limited and there is still a lack of highly efficient etiopathology-based treatment. It is partly due to the complexity and heterogenicity of the disease. It is estimated that around one-third of ischemic stroke is heritable, emphasizing the importance of genetic factors identification and targeting for therapeutic purposes. In this review, the authors provide an overview of the current knowledge of stroke genetics and its value in diagnostics, personalized treatment, and prognostication. As the scale of genetic testing increases and the cost decreases, integration of genetic data into clinical practice is inevitable, enabling assessing individual risk, providing personalized prognostic models and identifying new therapeutic targets and biomarkers. Although expanding stroke genetics data provides different diagnostics and treatment perspectives, there are some limitations and challenges to face. One of them is the threat of health disparities as non-European populations are underrepresented in genetic datasets. Finally, a deeper understanding of underlying mechanisms of potential targets is still lacking, delaying the application of novel therapies into routine clinical practice.